124 related articles for article (PubMed ID: 3386393)
1. Antagonism by N-methyl levallorphan-methane sulphonate (SR 58002 C) of morphine-elicited acute and chronic central and peripheral effects.
Sbacchi M; Colombo M; La Regina A; Petrillo P; Tavani A
Life Sci; 1988; 42(21):2079-89. PubMed ID: 3386393
[TBL] [Abstract][Full Text] [Related]
2. The peripheral narcotic antagonist N-allyl levallorphan-bromide (CM 32191) selectively prevents morphine antipropulsive action and buprenorphine in-vivo binding in the rat intestine.
Bianchi G; Fiocchi R; Peracchia F; Petrillo P; Tavani A; Manara L
J Pharm Pharmacol; 1984 May; 36(5):326-30. PubMed ID: 6145770
[TBL] [Abstract][Full Text] [Related]
3. Levallorphan methyl iodide (SR 58002), a potent narcotic antagonist with peripheral selectivity superior to that of other quaternary compounds.
Dragonetti M; Bianchetti A; Sacilotto R; Giudice A; Ferrarese N; Cattaneo C; Manara L
Life Sci; 1983; 33 Suppl 1():477-80. PubMed ID: 6664228
[TBL] [Abstract][Full Text] [Related]
4. Dissociation of morphine withdrawal diarrhea and jumping in mice by the peripherally selective opioid antagonist SR 58002 C.
Bianchetti A; Guidice A; Nava F; Manara L
Life Sci; 1986 Dec; 39(24):2297-303. PubMed ID: 3796195
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites.
Manara L; Bianchi G; Ferretti P; Tavani A
J Pharmacol Exp Ther; 1986 Jun; 237(3):945-9. PubMed ID: 3012075
[TBL] [Abstract][Full Text] [Related]
6. Morphine no longer blocks gastrointestinal transit but retains antinociceptive action in diallylnormorphine-pretreated rats.
Tavani A; Bianchi G; Manara L
Eur J Pharmacol; 1979 Oct; 59(1-2):151-4. PubMed ID: 510395
[TBL] [Abstract][Full Text] [Related]
7. Relative ability of N-methyl nalorphine and N-methyl levallorphan to prevent antinociception and intestinal transit inhibition in morphine treated rats.
Notarnicola A; Landi M; Bianchi G; Tavani A
Life Sci; 1983; 33 Suppl 1():481-4. PubMed ID: 6664229
[TBL] [Abstract][Full Text] [Related]
8. Morphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gut.
Bianchi G; Ferretti P; Recchia M; Rocchetti M; Tavani A; Manara L
Gastroenterology; 1983 Oct; 85(4):852-8. PubMed ID: 6193028
[TBL] [Abstract][Full Text] [Related]
9. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats.
Gmerek DE; Cowan A; Woods JH
J Pharmacol Exp Ther; 1986 Jan; 236(1):8-13. PubMed ID: 3941402
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists.
Russell J; Bass P; Goldberg LI; Schuster CR; Merz H
Eur J Pharmacol; 1982 Mar; 78(3):255-61. PubMed ID: 7200037
[TBL] [Abstract][Full Text] [Related]
11. Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity.
Bianchi G; Fiocchi R; Tavani A; Manara L
Life Sci; 1982 May; 30(22):1875-83. PubMed ID: 7109826
[TBL] [Abstract][Full Text] [Related]
12. Central and peripheral inhibition of gastrointestinal transit in rats: narcotics differ substantially by acting at either or both levels.
Peracchia F; Bianchi G; Fiocchi R; Petrillo P; Tavani A; Manara L
J Pharm Pharmacol; 1984 Oct; 36(10):699-701. PubMed ID: 6150093
[TBL] [Abstract][Full Text] [Related]
13. Different targets for i.v. vs. i.c.v. administered morphine for its effect on colonic motility in dogs.
Fioramonti J; Fargeas MJ; Bueno L
Eur J Pharmacol; 1985 Oct; 117(1):115-20. PubMed ID: 4085540
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of opiate mydriasis in mice.
Korczyn AD; Rock M
Br J Pharmacol; 1981 Aug; 73(4):807-10. PubMed ID: 7272583
[TBL] [Abstract][Full Text] [Related]
15. Antidiarrheal and central nervous system activities of SC-27166 (2-[3 - 5 - methyl - 1, 3, 4 - oxadiazol - 2 - yl) - 3, 3 - diphenylpropyl] - 2 - azabicyclo [2.2.2]octane), a new antidiarrheal agent, resulting from binding to opiate receptor sites of brain and myenteric plexus.
Mackerer CR; Brougham LR; East PF; Bloss JL; Dajani EZ; Clay GA
J Pharmacol Exp Ther; 1977 Dec; 203(3):527-38. PubMed ID: 200732
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of gastrointestinal transit by morphine and FK 33-824 in the rat and comparative narcotic antagonist properties of naloxone and its N-methyl quaternary analog.
Manara L; Bianchi G; Fiocchi R; Notarnicola A; Peracchia F; Tavani A
Life Sci; 1982 Sep 20-27; 31(12-13):1271-4. PubMed ID: 6183550
[TBL] [Abstract][Full Text] [Related]
17. Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ-opioid receptors in mice.
Matsumoto K; Umemoto H; Mori T; Akatsu R; Saito S; Tashima K; Shibasaki M; Kato S; Suzuki T; Horie S
Eur J Pharmacol; 2016 Jan; 771():220-8. PubMed ID: 26712376
[TBL] [Abstract][Full Text] [Related]
18. Interaction of U-69,593 with mu-, alpha- and kappa-opioid binding sites and its analgesic and intestinal effects in rats.
La Regina A; Petrillo P; Sbacchi M; Tavani A
Life Sci; 1988; 42(3):293-301. PubMed ID: 2826959
[TBL] [Abstract][Full Text] [Related]
19. Central and peripheral inhibitory effects of morphine on intestinal transit in mice.
Wong CL
Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):479-83. PubMed ID: 3747641
[TBL] [Abstract][Full Text] [Related]
20. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat.
Galligan JJ; Burks TF
J Pharmacol Exp Ther; 1983 Aug; 226(2):356-61. PubMed ID: 6875849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
